Biotech

All Articles

OS Therapies refiles $6M IPO to finance HER2 medication, preclinical ADCs

.OS Therapies are going to detail on the NYSE American stock substitution this morning using a $6.4 ...

ALX's fizzling CD47 reaction price delivers supply spiraling down

.ALX Oncology's stage 2 gastric cancer reaction fee has compromised. After viewing its CD47 blocker ...

Ionis axes eye condition from targets of Roche-partnered possibility after data disappoint

.An Additional of Ionis Pharmaceuticals' crucial midphase readouts has actually fallen short of assu...

Biogen's chief executive officer stated no unsafe sell 2023. He's ready to become strong

.While Biogen's pharma peers are hunting for late-stage properties with little bit of danger, chief ...

Instil refills pipeline in $2B biobucks manage ImmunOnco

.Instil Bio has actually been actually a biotech seeking a pipeline after it ditched its lead posses...

Biogen leaves Denali Alzheimer's collab

.Biogen has returned civil liberties to a very early Alzheimer's disease system to Denali Therapies,...

Takeda faucets brand new mind people oncology business-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of substantial leadership hirings, firings and ...

Vertex, beaten through AATD once again, drops 2 properties on discard heap

.Tip's attempt to address an unusual hereditary disease has actually reached an additional trouble. ...

Vir gains 3 T-cell engagers from Sanofi, gives up 25% of staff

.Vir Biotechnology's second-quarter incomes record had not been short of large headlines. The firm w...

Galapagos stops briefly CAR-T cell therapy trial over Parkinsonism instance

.Galapagos has paused application in a test of a BCMA-directed CAR-T cell therapy, pushing the brake...